The nation of Zimbabwe has turned down a significant American health deal worth $367m (272 million pounds) over five years over Washington's insistence on confidential information.
This rejection came to light after a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa felt the agreement was "skewed".
A government representative later explained that the US was requesting genetic material for research and commercial purposes but refused to guarantee the benefits from future medical innovations.
"We must now begin the challenging and unfortunate process of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for more negotiations to reach a agreement agreeable to all parties so the nation's vital HIV programme can continue.
Wider Background
This development follows a similar case in neighbouring Kenya, where a court suspended a related health funding agreement following concerns were raised about the security of citizens' medical information.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump stated its expenditure was "inefficient" and his government was seeking government-to-government deals to boost openness and responsibility.
Based on reports, Sixteen African countries have so far agreed to similar agreements, representing more than $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation could have provided immense benefits for Zimbabwean communities, especially the 1.2 million currently on antiretroviral therapy through US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to surrender its genetic material and health information for a long time, without any corresponding assurance of access to any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," his statement read.
"In essence, our nation would provide the raw materials for scientific discovery with no assurance that the resulting innovations would be available to our people if a future pandemic arise."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its push of bilateral deals were disrupting systems previously set up via the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework created to manage potential global health emergencies.
"This system is intended to ensure that when a nation contributes its data, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage ongoing dialogue with our US partners on how future collaboration might be arranged in a manner that honours the sovereignty and interests of both nations."
Medical Community Response
Medical experts said it understood the government's concerns, but suggested that negotiations need to persist since much of the country's Aids initiatives relied on external financing.
"If specific concerns exist, such as those relating to data governance or agreement terms, these can frequently be addressed through technical clarification and mutually agreed protections," it added.
This impasse highlights the continuing tensions between accepting much-needed international aid and protecting local interests in an ever more data-driven world.